Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets Hard-to-Treat cancers in early trial

NCT ID NCT06400472

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first finding a safe dose, then checking if the drug shrinks tumors. About 495 participants will take part over up to 4 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 575 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have one of the following solid tumor cancers: * Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC) * Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer * Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, TNBC, and high grade endometrioid cancer Exclusion Criteria: * Individual with known or suspected uncontrolled central nervous system (CNS) metastases * Individual with history of carcinomatous meningitis * Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection * Individual with evidence of corneal keratopathy or history of corneal transplant * Any serious unresolved toxicities from prior therapy * Significant cardiovascular disease * Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms) * History of pneumonitis/interstitial lung disease * Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast neoplasm cervical cancer colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm lung neoplasm malignant pancreatic neoplasm non-small cell lung carcinoma ovarian cancer ovarian neoplasm pancreatic neoplasm triple-negative breast carcinoma Uterine Cervical Neoplasms uterine cervix neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung Colorectal neoplasms Endometrial neoplasms Ovarian neoplasms Pancreatic neoplasm Triple negative breast neoplasms Uterine cervical neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    24 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cancer Institute Hospital of JFCR

    RECRUITING

    Tokyo, 135-8550, Japan

  • Cancer Research SA

    RECRUITING

    Adelaide, 5000, Australia

  • Centre Leon Berard

    RECRUITING

    Lyon, 69373, France

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Emory University

    NOT_YET_RECRUITING

    Atlanta, Georgia, 30308, United States

  • HonorHealth

    RECRUITING

    Scottsdale, Arizona, 85258, United States

  • Hospital Clinico Universitario de Valencia

    RECRUITING

    Valencia, 46010, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario Vall d'Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • Humanitas San Pio X

    RECRUITING

    Milan, 20159, Italy

  • Icon Cancer Centre South Brisbane

    RECRUITING

    QLD, 4101, Australia

  • Institut de Cancerologie de l'Ouest - site St-Herblain

    RECRUITING

    Saint-Herblain, 44805, France

  • Istituto Europeo di Oncologia

    RECRUITING

    Milan, 20141, Italy

  • NYU Langone Health - Long Island

    RECRUITING

    Mineola, New York, 11501, United States

  • National Cancer Center

    RECRUITING

    Goyang-si Gyeonggi-do, 10408, South Korea

  • National Cancer Center Hospital

    RECRUITING

    Tokyo, 104-0045, Japan

  • New York University (NYU) Clinical Cancer Center

    RECRUITING

    New York, New York, 10016, United States

  • Oncopole Claudius Regaud

    RECRUITING

    Toulouse, 31059, France

  • START Mountain Region

    RECRUITING

    West Valley City, Utah, 84119, United States

  • Shizuoka Cancer Center

    RECRUITING

    Shizuoka, 411-8777, Japan

  • South Texas Accelerated Research Therapeutics (START) Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • The Ohio State University (OSU) Wexner Medical Center

    RECRUITING

    Columbus, Ohio, 43210, United States

  • The University of Texas - MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030-4000, United States

  • University of California, San Diego (UCSD) - Moores Cancer Center

    RECRUITING

    La Jolla, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.